ArticleFunctional & integrative genomics2026
Transcriptome profiling reveals the role of XIST/miR-335-5p regulatory axis as a crucial mediator of chemoresistance in esophageal cancer by influencing EMT and Ferroptosis.
Article in Functional & integrative genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Emerging evidence suggests that long non-coding RNAs (lncRNAs) in the development of chemoresistance in esophageal cancer (EC). In this study, we examined the role of the lncRNA XIST in tumor progression and cisplatin resistance. Transcriptomic profiling of parental (KYSE140) and cisplatin-resistant (CISR) EC cell lines identified XIST as a key regulator associated with the resistant phenotype. Clinical evaluation of EC specimens further revealed significant upregulation of XIST in tumor tissues, particularly in post-neoadjuvant chemotherapy (NACT) and non-responder patient groups. To elucidate its functional significance, Transfection of CISR cells were performed using si-XIST or miR-335-5p mimic, along with respective controls, followed by assessment of proliferation, migration, invasion, and cisplatin sensitivity (p < 0.05). Weighted gene co-expression network analysis (WGCNA) demonstrated a strong association of XIST with epithelial-mesenchymal transition (EMT)-related pathway, while miRNet predicted a regulatory interaction among XIST, miR-335-5p, and ZEB2. The direct binding interactions of miR-335-5p with XIST and ZEB2 were confirmed using dual-luciferase reporter assays and RNA pull-down experiments (p < 0.05). Functional and molecular analyses revealed that XIST promotes tumorigenesis and cisplatin resistance via miR-335-5p sponging, which resulted in the upregulation of ZEB2 and the induction of EMT. Additionally, XIST was found to suppress ferroptosis via the miR-335-5p axis, as confirmed through qPCR, western blotting, iron accumulation, and lipid peroxidation assays (p < 0.05). collectively, these results suggest that the XIST/miR-335-5p regulatory axis plays a pivotal role in EC chemoresistance by enhancing EMT and suppressing ferroptosis, highlighting its potential as a therapeutic target for overcoming treatment resistance.
Indexed as
Identifiers
42347967What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.